169335-35-7

Basic information

• Product Name: Pyrazinecarboxylic acid, 5-fluoro-, methyl ester (9CI)
• Synonyms: Pyrazinecarboxylic acid, 5-fluoro-, methyl ester (9CI)
• CAS NO: 169335-35-7
• Molecular Formula: C6H5FN2O2
• Molecular Weight: 156.1145032
• Product Categories: CARBOXYLICESTER;HALIDE;GLYCINESCAFFOLD
• Mol File: 169335-35-7.mol

Chemical Properties

• Boiling Point: 220.1±35.0 °C(Predicted)
• Appearance: /
• Density: 1.323±0.06 g/cm3(Predicted)
• PKA: -4.25±0.10(Predicted)
• CAS DataBase Reference: Pyrazinecarboxylic acid, 5-fluoro-, methyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrazinecarboxylic acid, 5-fluoro-, methyl ester (9CI)(169335-35-7)
• EPA Substance Registry System: Pyrazinecarboxylic acid, 5-fluoro-, methyl ester (9CI)(169335-35-7)

Safety Data

• Hazardous Substances Data: 169335-35-7(Hazardous Substances Data)

Upstream product

• 33332-25-1 methyl 5-chloropyrazine-2-carboxylate 
• 88625-23-4 5-chloropyrazine-2-carbonyl chloride 

Downstream Products

• 1427744-12-4 5-[2(R)-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-propionylamino]-pyrazine-2-carboxylic acid methyl ester 
• 1427744-25-9 2(R)-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-N-(5-hydroxymethyl-pyrazin-2-yl)propionamide 
• 710321-53-2 2(R)-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-N-(5-methanesulfonylmethyl-pyrazin-2-yl)-propionamide 

Relevant articles and documents

Pyrazinoic Acid Esters with Broad Spectrum in Vitro Antimycobacterial Activity

A series of substituted pyrazinoic acid esters has been prepared and examined for their in vitro activity against Mycobacterium avium and Mycobacterium kansasii as well as mycobacterium tuberculosis.Modification of both the pyrazine nucleus and the ester functionality have been very successfull in expanding the activity of pyrazinamide to include M. avium and M. kansasii, organisms normally not susceptible to pyrazinamide.Several of these compounds have activities 100-1000-fold greater than that of pyrazinamide against M. tuberculosis.

Identification of RO4597014, a glucokinase activator studied in the clinic for the treatment of type 2 diabetes

To resolve the metabolite redox cycling associated with our earlier clinical compound 2, we carried out lead optimization of lead molecule 1. Compound 4 showed improved lipophilic ligand efficiency and demonstrated robust glucose lowering in diet-induced obese mice without a liability in predictive preclinical drug safety studies. Thus, it was selected as a clinical candidate and further studied in type 2 diabetic patients. Clinical data suggests no evidence of metabolite cycling, which is consistent with the preclinical profiling of metabolism.

5-SUBSTITUTED-PYRAZINE OR PYRIDINE GLUCOKINASE ACTIVATORS

The present invention provides a compound according to formula (I) where the substituent designations are provided in the specification. Pharmaceutical compositions comprising a compound according to formula (I) are also provided, said compounds being glucokinase activators which are useful in the treatment of type II diabetes.